Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 14 Pain 13 Cancer Pain 6 Breakthrough Pain 4 Breakthrough Cancer Pain 3 Chronic Pain 2 Burns 2 Anemia, Sickle Cell 2 Agnosia 2 Waldenstrom Macroglobulinemia 1 Vulvar Neoplasms 1 Vipoma 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Thymoma 1 Thrombocythemia, Essential 1 Testicular Neoplasms 1 Stomach Neoplasms 1 Standard Opioid Analgesic Treatment of Cancer-related Chronic Pain. 1 Squamous Cell Carcinoma of Head and Neck 1 Somatostatinoma 1 Small Cell Lung Carcinoma 1 Sezary Syndrome 1 Sarcoma 1 Salivary Gland Neoplasms 1 Respiratory Insufficiency 1 Rectal Neoplasms 1 Quality of Life 1

Interventions

Tamoxifen 1 Fentanyl 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Quality of Life × Fentanyl × Clear all

NCT01936636 2015-11-05

RELIEF

Galena Biopharma, Inc.

Quality of Life

Data powered by HemOnc (CC BY 4.0) Colophon ⚡